Skip to content
OpenCapital
Get started

Atara Biotherapeutics ATRA Q4 2024 Annual earnings

Reported March 7, 2025 · Before market open

Revenue$32.8MBeat by $12.2M
EPS-$1.19Beat by $2.63
Revenue estimate$20.6M
EPS estimate-$3.82

Next report

Aug 10, 2026 (In 1 week)
Revenue estimate$550.0K
EPS estimate-$0.32

Versus estimates

Revenue

Q1 2026$516.0KMiss by $2.4MQ4 2025$1.6MMiss by $1.7MQ3 2025$3.5MBeat by $2.8MQ2 2025$17.6MBeat by $15.8MQ1 2025$98.1MBeat by $93.8M
Q4 2024$32.8MBeat by $12.2M

Diluted EPS

Q1 2026-$0.29Beat by $0.04Q4 2025-$0.25Miss by $0.16Q3 2025-$0.32Beat by $0.51Q2 2025$0.19Beat by $0.51Q1 2025$3.50Beat by $6.57
Q4 2024-$1.19Beat by $2.63

Ask the moment Atara Biotherapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Atara Biotherapeutics report Q4 2024 earnings?
Atara Biotherapeutics (ATRA) reported Q4 2024 earnings on March 7, 2025 before market open.
What were Atara Biotherapeutics's Q4 2024 revenue and EPS?
Atara Biotherapeutics reported revenue of $32.8M and eps of $-1.19 for Q4 2024.
Did Atara Biotherapeutics beat estimates in Q4 2024?
Revenue beat the consensus estimate of $20.6M by $12.2M. EPS beat the consensus estimate of $-3.82 by $2.63.
Where can I find Atara Biotherapeutics's Q4 2024 SEC filings?
You can read the 10-K periodic report (0000950170-25-035507) directly on SEC EDGAR. The filing index links above go to sec.gov.